(Q38017914)

27 August 2017

title

State of the art in the treatment of Hodgkin lymphoma (English)

1 reference

27 August 2017

Peter Borchmann

1

1 reference

27 August 2017

Dennis A Eichenauer

series ordinal

2

1 reference

27 August 2017

Andreas Engert

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

12 June 2012

1 reference

Nature Reviews Clinical Oncology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

450-459

1 reference

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Twenty years of MOPP therapy for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

How much does it cost to treat children with Hodgkin lymphoma in Africa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 t

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ESHAP is an active regimen for relapsing Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Long-term cause-specific mortality of patients treated for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Long-term follow-up of Hodgkin's disease trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Seattle Genetics rare cancer drug sails through accelerated approval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Hodgkin's disease in the elderly: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.91

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease

31 March 2020

1 reference

12 December 2020

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group

1 reference

12 December 2020

New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group

1 reference

12 December 2020

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

1 reference

12 December 2020

10.1038/NRCLINONC.2012.91

Identifiers

DOI

1 reference

27 August 2017

1 reference